EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma

Tomoki Makino, Hiroshi Miyata, Takushi Yasuda iD, Yuko Kitagawa, Kei Muro, Jae-Hyun Park, Tetsuro Hikichi, Takahiro Hasegawa, Kenji Igarashi, Motofumi Iguchi, Yasuhide Masaoka, Masahiko Yano und 1 weitere

Esophagus · 2024-10 · 21 (4) · 447-455

DOI: 10.1007/s10388-024-01072-w ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Esophagus, online erschienen am 11.07.2024. Verfasst von Tomoki Makino und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. Hauptthemen laut MEDLINE: Cancer Vaccines, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: OncoTherapy Science Inc., Shionogi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

S-588410, a cancer peptide vaccine (CPV), comprises five HLA-A*24:02-restricted peptides from five cancer-testis antigens. In a phase 2 study, S-588410 was well-tolerated and exhibited antitumor efficacy in patients with urothelial cancer. Therefore, we aimed to evaluate the efficacy, immune response, and safety of S-588410 in patients with completely resected esophageal squamous cell carcinoma (ESCC).

Methods

This phase 3 study involved patients with HLA-A*24:02-positive and lymph node metastasis-positive ESCC who received neoadjuvant therapy followed by curative resection. After randomization, patients were administered S-588410 and placebo (both emulsified with Montanide™ ISA 51VG) subcutaneously. The primary endpoint was relapse-free survival (RFS). The secondary endpoints were overall survival (OS), cytotoxic T-lymphocyte (CTL) induction, and safety. Statistical significance was tested using the one-sided weighted log-rank test with the Fleming–Harrington class of weights.

Results

A total of 276 patients were randomized ( N = 138/group). The median RFS was 84.3 and 84.1 weeks in the S-588410 and placebo groups, respectively ( P = 0.8156), whereas the median OS was 236.3 weeks and not reached, respectively ( P = 0.6533). CTL induction was observed in 132/134 (98.5%) patients who received S-588410 within 12 weeks. Injection site reactions (137/140 patients [97.9%]) were the most frequent treatment-emergent adverse events in the S-588410 group. Prolonged survival was observed in S-588410-treated patients with upper thoracic ESCC, grade 3 injection-site reactions, or high CTL intensity.

Conclusions

S-588410 induced immune response and had acceptable safety but failed to reach the primary endpoint. A high CTL induction rate and intensity may be critical for prolonging survival during future CPV development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaHumansMaleFemaleMiddle AgedAgedDouble-Blind MethodVaccines, SubunitNeoadjuvant TherapyT-Lymphocytes, CytotoxicTreatment OutcomeLymphatic MetastasisHLA-A24 AntigenDisease-Free SurvivalEsophagectomyCarcinoma, Squamous Cell

Stichwörter der Autor:innen

Adjuvant therapyCancer peptide vaccineCytotoxic T lymphocytesEsophageal squamous cell carcinomaS-588410

Substanzen

Cancer VaccinesVaccines, SubunitHLA-A24 AntigenHLA-A*24:02 antigen

Autor:innen und Institutionen

  • Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Surgery, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan. takushi-yasuda6008@med.kindai.ac.jp.
  • Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
  • OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan.

ORCID-Profile: Takushi Yasuda

Förderung

  • OncoTherapy Science Inc.
  • Shionogi

Zitieren

APA

Makino, T., Miyata, H., Yasuda, T., Kitagawa, Y., Muro, K., Park, J. H., Hikichi, T., Hasegawa, T., Igarashi, K., Iguchi, M., Masaoka, Y., Yano, M., & Doki, Y. (2024). A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma. Esophagus, 21(4), 447-455. https://doi.org/10.1007/s10388-024-01072-w

Vancouver

Makino T, Miyata H, Yasuda T, Kitagawa Y, Muro K, Park JH, et al. A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma. Esophagus. 2024;21(4):447-455. doi:10.1007/s10388-024-01072-w

BibTeX
@article{Makino2024,
  author = {Makino, Tomoki and Miyata, Hiroshi and Yasuda, Takushi and Kitagawa, Yuko and Muro, Kei and Park, Jae-Hyun and Hikichi, Tetsuro and Hasegawa, Takahiro and Igarashi, Kenji and Iguchi, Motofumi and Masaoka, Yasuhide and Yano, Masahiko and Doki, Yuichiro},
  title = {A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma},
  journal = {Esophagus},
  year = {2024},
  volume = {21},
  number = {4},
  pages = {447--455},
  doi = {10.1007/s10388-024-01072-w}
}
Kostenlos starten →